CollPlant Biotechnologies Ltd. (CLGN) is a Biotechnology company in the Healthcare sector, currently trading at $0.34. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is CLGN = $13 (+3557.1% upside).
Valuation: CLGN trades at a trailing Price-to-Earnings (P/E) of -0.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.01.
Financials: revenue is $2M, +1276.8%/yr average growth. Net income is $11M (loss), growing at -15.9%/yr. Net profit margin is -484.6% (negative). Gross margin is 26.3% (+60.1 pp trend).
Balance sheet: total debt is $3M against $6M equity (Debt-to-Equity (D/E) ratio 0.47, conservative). Current ratio is 2.53 (strong liquidity). Debt-to-assets is 26.4%. Total assets: $11M.
Analyst outlook: 4 / 5 analysts rate CLGN as buy (80%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 29/100 (Fail), Future 94/100 (Pass), Income 10/100 (Fail).
